The renoprotecive effects of GLP1-RA were recently confirmed by the FLOW trial, indicating that among patients with type 2 diabetes and chronic kidney disease, semaglutide therapy was associated with a significantly reduced risk of kidney disease progression, cardiovascular events, and overall mortality [12]. This evidence concerns the gene GLP1R and chronic kidney disease.